

January 2027 BASAGLAR® (insulin glargine) and Trulicity® (dulaglutide) Limited Duration Rebate Announcement

Effective January 1, 2027, the following products will undergo price reductions in Wholesale Acquisition Cost (WAC): BASAGLAR® U-100 KwikPen® (~71% WAC reduction) and Trulicity® Single-dose pen (all NDCs) (~ 40% WAC reduction). The decision to reduce the WAC prices of BASAGLAR and Trulicity continues Lilly's efforts to expand appropriate patient access to our medicines.

In an effort to avoid supply chain and patient access disruptions, **Lilly will be offering a Limited Duration Rebate on BASAGLAR® U-100 KwikPen and Trulicity® Pen (all NDCs) purchased at WAC from participating Lilly Authorized Distributors of Record during the period of December 22nd – December 31st, 2026.** Lilly will not be offering a “shelf stock adjustment” after the price decrease on January 1st, 2027.

Price Decrease Details:

Product	NDC
BASAGLAR U-100 KWIKPEN 3mL X 5	00002-7715-59
TRULICITY 0.75 mg/0.5 mL X 4	00002-1433-80
TRULICITY 1.5 mg/0.5 mL X 4	00002-1434-80
TRULICITY 3.0 mg/0.5 mL X 4	00002-2236-80
TRULICITY 4.5 mg/0.5 mL X 4	00002-3182-80

- To receive the rebate, customers will purchase affected product from a participating Lilly Authorized Distributor of Record (ADR) as they normally do during the limited duration period of December 22nd – December 31st, 2026.
- Lilly will partner with Distributors to credit pharmacies the rebate amount on eligible purchases after a validation process.
- Eligible Product that is purchased at any contracted or up-front discount (except for discounts which may be available from wholesaler subject to agreement between customer/wholesaler) will not be eligible for this rebate.
- No rebate will be provided on any purchase of Eligible Product at a contracted price more than five percent (5%) below WAC.

The expectation is that the validation process and wholesaler credit process for rebates will be completed in a timely manner.

For questions related to this program, please email Lillytrade@lilly.com

Please see the full [Prescribing Information](#) for Trulicity, including Boxed Warning, and [Medication Guide](#).

BASAGLAR®, KwikPen®, and Trulicity® and its delivery device base are registered trademarks of Eli Lilly and Company, its subsidiaries or affiliates.